Answers are grounded in this paper and cite their sources.
Evaluates the effects of intravenous immune globulin on autoimmune disorders, suggesting its broad efficacy.
Intravenous immune globulin has been used in the treatment of primary and secondary antibody deficiencies for more than 25 years. It is a safe preparation with no long-term side effects. Intravenous immune globulin was first demonstrated to be effective in an autoimmune disorder — idiopathic thrombocytopenic purpura — two decades ago. Since then, it has been established to be efficacious in the treatment of the Guillain–Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, corticosteroid-resistant dermatomyositis, and Kawasaki's syndrome and in the prevention of graft-versus-host disease in recipients of allogeneic bone marrow transplants. Benefits have been reported in many other autoimmune . . .
No takes yet. Share an insight, caveat, or question.
Kazatchkine et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: